LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 58

Search options

  1. Article ; Online: Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.

    Dennis, Michael J / Bylsma, Sophia / Madlensky, Lisa / Pagadala, Meghana S / Carter, Hannah / Patel, Sandip P

    Frontiers in immunology

    2024  Volume 15, Page(s) 1322187

    Abstract: Background: Impaired DNA damage response (DDR) can affect immune checkpoint inhibitors (ICI) efficacy and lead to heightened immune activation. We assessed the impact of pathogenic or likely pathogenic (P/LP) germline DDR mutations on ICI response and ... ...

    Abstract Background: Impaired DNA damage response (DDR) can affect immune checkpoint inhibitors (ICI) efficacy and lead to heightened immune activation. We assessed the impact of pathogenic or likely pathogenic (P/LP) germline DDR mutations on ICI response and toxicity.
    Materials and methods: A retrospective analysis of 131 cancer patients with germline DNA testing and ICI treatment was performed.
    Results: Ninety-two patients were DDR-negative (DDR-), and 39 had ≥1 DDR mutation (DDR+). DDR+ patients showed higher objective response rates (ORRs) compared to DDR- in univariate and multivariable analyses, adjusting for age and metastatic disease (62% vs. 23%, unadjusted OR = 5.41; 95% CI, 2.41-12.14; adjusted OR 5.94; 95% CI, 2.35-15.06). Similar results were seen in mismatch repair (MMR), DDR pathways with intact MMR (DDR+MMRi), and homologous recombination (HR) subgroups versus DDR- (adjusted OR MMR = 24.52; 95% CI 2.72-221.38, DDR+MMRi = 4.26; 95% CI, 1.57-11.59, HR = 4.74; 95% CI, 1.49-15.11). DDR+ patients also had higher ORRs with concurrent chemotherapy (82% vs. 39% DDR-, p=0.03) or concurrent tyrosine kinase inhibitors (50% vs. 5% DDR-, p=0.03). No significant differences in immune-related adverse events were observed between DDR+ and DDR- cohorts.
    Conclusion: P/LP germline DDR mutations may enhance ICI response without significant additional toxicity.
    MeSH term(s) Humans ; DNA Damage ; Immune Checkpoint Inhibitors/adverse effects ; Retrospective Studies ; Mutation ; Neoplasms/drug therapy ; Neoplasms/genetics ; Biomarkers, Tumor/genetics ; DNA Mismatch Repair/genetics ; Germ Cells
    Chemical Substances Immune Checkpoint Inhibitors ; Biomarkers, Tumor
    Language English
    Publishing date 2024-01-29
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1322187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges.

    O'Leary, Caroline L / Pierce, Nicole / Patel, Sandip P / Naidoo, Jarushka

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2023  Volume 19, Issue 3, Page(s) 395–408

    Abstract: Immune checkpoint inhibitors have become standard-of-care for the treatment of NSCLC; however, their use brings with it the risk of a unique set of inflammatory side effects, termed immune-related adverse events (irAEs). The recognition, diagnosis, and ... ...

    Abstract Immune checkpoint inhibitors have become standard-of-care for the treatment of NSCLC; however, their use brings with it the risk of a unique set of inflammatory side effects, termed immune-related adverse events (irAEs). The recognition, diagnosis, and management of irAEs have become essential to clinical practice, with the potential for high-grade toxicities affecting treatment decision-making. This manuscript provides a state-of-the-art review of irAEs as they pertain to patients with NSCLC, by summarizing the common and severe toxicities of the standard immune checkpoint inhibitor regimens and clinical treatment settings relevant to this disease and future directions.
    MeSH term(s) Humans ; Lung Neoplasms/therapy ; Immunotherapy/adverse effects ; Carcinoma, Non-Small-Cell Lung/therapy ; Immune Checkpoint Inhibitors/therapeutic use
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-11-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2023.11.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.

    Othus, Megan / Patel, Sandip P / Chae, Young K / Dietrich, Eliana / Streicher, Howard / Sharon, Elad / Kurzrock, Razelle

    Journal of the National Cancer Institute

    2024  Volume 116, Issue 5, Page(s) 673–680

    Abstract: Background: RECIST criteria for progressive disease, partial response, and complete response, reflecting +20%, -30%, and -100% tumor size changes, respectively, are critical outcome variables in oncology clinical trials. Herein, we evaluated post- ... ...

    Abstract Background: RECIST criteria for progressive disease, partial response, and complete response, reflecting +20%, -30%, and -100% tumor size changes, respectively, are critical outcome variables in oncology clinical trials. Herein, we evaluated post-immunotherapy tumor size change correlation with outcomes.
    Methods: We used a unique clinical trial data resource, a multicenter basket trial in patients with rare solid tumors treated with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) between 2017 and 2023 (National Cancer Institute/Southwest Oncology Group-sponsored DART trial [NCT02834013]) (open at 1083 sites at its peak). Outcome associations were evaluated by survival analysis techniques including Martingale residuals.
    Results: In 638 evaluable patients, we found strong linear relationships between percent change in tumor measurement up to a 40%-50% increase and progression-free (PFS) and overall survival (OS) (both Cox regression P < .001; landmark analyses based on day 65). Pearson R correlation between survival estimates and tumor change category were -0.94, -0.89, and -0.89 (PFS) and -0.84, -0.90, and -0.90 (OS) for median, 6-month (PFS), and 1-year (OS) and for 1-year (PFS) and 2-year (OS) estimates.
    Conclusions: Percent change in tumor measurement per RECISTv1.1 (the sum of longest dimensions of target lesions) has a linear association with PFS and OS up to a 40% to 50% increase in tumor measurement in this cohort of patients with rare cancers who received combination immune checkpoint blockade. Quantitative first scan tumor measurement changes include important information to evaluate the potential efficacy of a therapy beyond the proportion of patients who achieve an objective response.
    MeSH term(s) Humans ; Male ; Female ; Immunotherapy/methods ; Middle Aged ; Neoplasms/pathology ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neoplasms/therapy ; Neoplasms/immunology ; Aged ; Ipilimumab/therapeutic use ; Ipilimumab/administration & dosage ; Adult ; Nivolumab/therapeutic use ; Response Evaluation Criteria in Solid Tumors ; Immune Checkpoint Inhibitors/therapeutic use ; Tumor Burden ; Progression-Free Survival ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
    Chemical Substances Ipilimumab ; Nivolumab (31YO63LBSN) ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2024-01-19
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Multicenter Study
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djae009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Integrating clinical research into electronic health record workflows to support a learning health system.

    Goldhaber, Nicole H / Jacobs, Marni B / Laurent, Louise C / Knight, Rob / Zhu, Wenhong / Pham, Dean / Tran, Allen / Patel, Sandip P / Hogarth, Michael / Longhurst, Christopher A

    JAMIA open

    2024  Volume 7, Issue 2, Page(s) ooae023

    Abstract: Objective: Integrating clinical research into routine clinical care workflows within electronic health record systems (EHRs) can be challenging, expensive, and labor-intensive. This case study presents a large-scale clinical research project conducted ... ...

    Abstract Objective: Integrating clinical research into routine clinical care workflows within electronic health record systems (EHRs) can be challenging, expensive, and labor-intensive. This case study presents a large-scale clinical research project conducted entirely within a commercial EHR during the COVID-19 pandemic.
    Case report: The UCSD and UCSDH COVID-19 NeutraliZing Antibody Project (ZAP) aimed to evaluate antibody levels to SARS-CoV-2 virus in a large population at an academic medical center and examine the association between antibody levels and subsequent infection diagnosis.
    Results: The project rapidly and successfully enrolled and consented over 2000 participants, integrating the research trial with standing COVID-19 testing operations, staff, lab, and mobile applications. EHR-integration increased enrollment, ease of scheduling, survey distribution, and return of research results at a low cost by utilizing existing resources.
    Conclusion: The case study highlights the potential benefits of EHR-integrated clinical research, expanding their reach across multiple health systems and facilitating rapid learning during a global health crisis.
    Language English
    Publishing date 2024-05-15
    Publishing country United States
    Document type Case Reports
    ISSN 2574-2531
    ISSN (online) 2574-2531
    DOI 10.1093/jamiaopen/ooae023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.

    Patel, Sandip P / Othus, Megan / Chae, Young Kwang / Kurzrock, Razelle

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2020  Volume 26, Issue 10, Page(s) 2434

    MeSH term(s) Antineoplastic Agents, Immunological/adverse effects ; Humans ; Ipilimumab/therapeutic use ; Melanoma/drug therapy ; Melanoma/genetics ; Nivolumab/therapeutic use
    Chemical Substances Antineoplastic Agents, Immunological ; Ipilimumab ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2020-05-15
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-20-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.

    Gao, Yinjie / Stein, Michelle M / Kase, Matthew / Cummings, Amy L / Bharanikumar, Ramit / Lau, Denise / Garon, Edward B / Patel, Sandip P

    Cancer immunology, immunotherapy : CII

    2022  Volume 72, Issue 2, Page(s) 339–350

    Abstract: Background: Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not ... ...

    Abstract Background: Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not consistently indicative of ICB response. Other markers within the tumor immune microenvironment (TIME) may better reflect ICB response and/or resistance mechanisms, but an understanding of how TIMEs differ between stage III and IV NSCLC has not been explored.
    Methods: Real-world data from unresectable, stage III-IV, non-squamous, pretreatment NSCLCs (stage III n = 106, stage IV n = 285) were retrospectively analyzed. PD-L1 immunohistochemistry (IHC) was compared to CD274 gene expression. Then, differential gene expression levels, pathway enrichment, and immune infiltrate between stages were calculated from whole-transcriptome RNA-seq. Analyses were stratified by EGFR status.
    Results: PD-L1 IHC and CD274 expression in tumor cells were highly correlated (n = 295, P < 2.2e-16, ⍴ = 0.74). CTLA4 expression was significantly increased in stage III tumors (P = 1.32e-04), while no differences were observed for other ICB-related genes. Metabolic pathway activity was significantly enriched in stage IV tumors (P = 0.004), whereas several immune-related KEGG pathways were enriched in stage III. Stage IV tumors had significantly increased macrophage infiltration (P = 0.0214), and stage III tumors had a significantly higher proportion of CD4 + T cells (P = 0.017). CD4 + T cells were also relatively more abundant in EGFR-mutant tumors vs. wild-type (P = 0.0081).
    Conclusion: Directly comparing the TIMEs of stage III and IV NSCLC, these results carry implications for further studies of ICB response in non-resectable stage III NSCLC and guide further research of prognostic biomarkers and therapeutic targets.
    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; B7-H1 Antigen/metabolism ; Retrospective Studies ; Biomarkers ; Tumor Microenvironment ; Immune Checkpoint Inhibitors/therapeutic use ; ErbB Receptors ; Biomarkers, Tumor
    Chemical Substances B7-H1 Antigen ; Biomarkers ; Immune Checkpoint Inhibitors ; ErbB Receptors (EC 2.7.10.1) ; Biomarkers, Tumor
    Language English
    Publishing date 2022-07-26
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 195342-4
    ISSN 1432-0851 ; 0340-7004
    ISSN (online) 1432-0851
    ISSN 0340-7004
    DOI 10.1007/s00262-022-03252-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

    Patel, Sandip P / Alonso-Gordoa, Teresa / Banerjee, Susana / Wang, Ding / Naidoo, Jarushka / Standifer, Nathan E / Palmer, Doug C / Cheng, Lin-Yang / Kourtesis, Panagiotis / Ascierto, Maria L / Das, Mayukh / Diamond, Jennifer R / Hellmann, Matthew D / Carneiro, Benedito A

    Journal for immunotherapy of cancer

    2024  Volume 12, Issue 2

    Abstract: Background: The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated safety, ... ...

    Abstract Background: The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated safety, antitumor activity, and pharmacodynamics in patients with advanced solid tumors.
    Main body: Immunotherapy-naïve patients aged ≥18 years with advanced disease, Eastern Cooperative Oncology Group performance status of 0-1, and 1-3 prior lines of systemic therapy in the recurrent/metastatic setting were enrolled. In part 1 (dose escalation), patients received durvalumab 1500 mg every 4 weeks (Q4W) with increasing doses of monalizumab Q2W/Q4W (n=15). Dose expansion in part 1 included patients with cervical cancer (n=15; durvalumab 1500 mg Q4W and monalizumab 750 mg Q2W) or metastatic microsatellite stable (MSS)-colorectal cancer (CRC) (n=15; durvalumab 1500 mg Q4W and monalizumab 750 mg Q4W). In part 2 (dose expansion), patients with MSS-CRC (n=40), non-small cell lung cancer (NSCLC; n=20), MSS-endometrial cancer (n=40), or ovarian cancer (n=40) received durvalumab 1500 mg Q4W and monalizumab 750 mg Q2W. The primary endpoint was safety. Secondary endpoints included antitumor activity per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1). Exploratory analyses included assessment of T-cell and natural killer (NK) cell activation and proliferation in peripheral blood and the tumor microenvironment (TME). The study enrolled 185 patients (part 1, 45; part 2, 140). No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. In part 2, the most common treatment-related adverse events were fatigue (12.1%), asthenia (9.3%), diarrhea (9.3%), pruritus (7.9%), and pyrexia (7.1%). In the expansion cohorts, response rates were 0% (cervical), 7.7% (MSS-CRC), 10% (NSCLC), 5.4% (ovarian), and 0% (MSS-endometrial). Sustained NK cell activation, CD8
    Conclusions: Although efficacy was modest, monalizumab plus durvalumab was well tolerated and encouraging immune activation was observed in the peripheral blood and TME.
    Trial registration number: NCT02671435.
    MeSH term(s) Female ; Humans ; Adolescent ; Adult ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Ligands ; Lung Neoplasms/drug therapy ; Tumor Microenvironment ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized
    Chemical Substances durvalumab (28X28X9OKV) ; monalizumab (3ZXZ2V0588) ; Ligands ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-02-02
    Publishing country England
    Document type Clinical Trial, Phase II ; Clinical Trial, Phase I ; Journal Article
    ZDB-ID 2719863-7
    ISSN 2051-1426 ; 2051-1426
    ISSN (online) 2051-1426
    ISSN 2051-1426
    DOI 10.1136/jitc-2023-007340
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.

    Patel, Sandip P / Guadarrama, Elizabeth / Chae, Young Kwang / Dennis, Michael J / Powers, Benjamin C / Liao, Chih-Yi / Ferri, William A / George, Thomas J / Sharon, Elad / Ryan, Christopher W / Othus, Megan / Lopez, Gabby / Blanke, Charles D / Kurzrock, Razelle

    Cancer

    2024  

    Abstract: Introduction: Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open-label study was ... ...

    Abstract Introduction: Most patients with advanced gallbladder cancer are treated with multiagent chemotherapy. Immune checkpoint inhibitors offer the possibility of a durable response with less toxicity. This prospective, multicenter, open-label study was designed to evaluate the anticancer activity of nivolumab plus ipilimumab in patients with advanced gallbladder cancer.
    Methods: Nineteen patients with advanced gallbladder cancer refractory to ≥1 previous therapy received nivolumab 240 mg intravenously every 2 weeks and ipilimumab 1 mg/kg intravenously every 6 weeks until disease progression or unacceptable toxicity. The primary end point was confirmed radiographic overall response rate (ORR) (complete response [CR] + partial response [PR] confirmed on subsequent scan); secondary end points included unconfirmed overall response, clinical benefit rate (confirmed and unconfirmed responses + stable disease >6 months), progression-free survival, overall survival, and toxicity.
    Results: The confirmed ORR was 16% (CR, n = 1 [5%]; PR, n = 2 [11%]); all were microsatellite stable, and the confirmed CR had undetectable programmed death-ligand 1 by immunohistochemistry. The unconfirmed ORR and clinical benefit rates were both 32%. The median duration of response was 14.8 months (range, 4-35.1+ months). The 6-month progression-free survival was 26% (95% CI, 12-55). The median overall survival was 7.0 months (95% CI, 3.9-19.1). The most common toxicities were fatigue (32%), anemia (26%), and anorexia (26%). Aspartate aminotransferase elevation was the most common grade 3/4 toxicity (11%). There was 1 possibly related death (sepsis with attendant hepatic failure).
    Conclusions: Ipilimumab plus nivolumab was well tolerated and showed modest efficacy with durable responses in previously treated patients with advanced gallbladder cancer.
    Clinical trial registration: NCT02834013 (ClincialTrials.gov).
    Plain language summary: This prospective study assessed the efficacy and safety of nivolumab plus ipilimumab in 19 patients with advanced gallbladder cancer refractory to previous therapy. The combination demonstrated modest efficacy with a 16% confirmed overall response rate, durable responses, and manageable toxicities, suggesting potential benefits for this challenging patient population.
    Language English
    Publishing date 2024-02-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.35243
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.

    Patel, Sandip P / Othus, Megan / Chae, Young Kwang / Dennis, Michael J / Gordon, Sarah / Mutch, David / Samlowski, Wolfram / Robinson, William R Rusty / Sharon, Elad / Ryan, Christopher / Lopez, Gabby / Plets, Melissa / Blanke, Charles / Kurzrock, Razelle

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 30, Issue 1, Page(s) 33–38

    Abstract: Purpose: The efficacy of immune checkpoint blockade in gestational trophoblastic neoplasia (GTN) remains uncertain. We report the results of the GTN cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).: Patients and ... ...

    Abstract Purpose: The efficacy of immune checkpoint blockade in gestational trophoblastic neoplasia (GTN) remains uncertain. We report the results of the GTN cohort of SWOG S1609 dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Patients and methods: This prospective, open-label phase II trial evaluated ipilimumab plus nivolumab across multiple rare tumor cohorts, including GTN. Eligible patients received nivolumab 240 mg, i.v. every 2 weeks and ipilimumab 1 mg/kg i.v. every 6 weeks. The primary endpoint was overall response rate [ORR; complete response (CR) + partial response (PR)] by quantitative serum beta human chorionic gonadotropin (β-hCG); secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity.
    Results: Four patients with refractory GTN enrolled and received therapy. At 11 months of ongoing follow-up, 3 of 4 patients responded [ORR = 75% (CR, 25%, n = 1, tumor mutation burden = 1 mutation/megabase; PD-L1 tumor proportion score = 50%); PR, 50%, n = 2)]. Responders included malignant gestational trophoblastic neoplasm (n = 1, CR, PFS 11+ months) and choriocarcinoma (n = 2, both PRs, PFS 10+ and 6+ months). One patient with epithelioid trophoblastic tumor experienced disease progression. The 6-month PFS was 75% [95% confidence interval (CI), 43%-100%], and the median PFS was not reached (range, 35-339+ days); all 4 patients were alive at last follow-up. Two patients experienced grade 3 immune-related toxicity (arthralgia and colitis); there were no grade ≥4 events.
    Conclusions: Ipilimumab plus nivolumab demonstrated efficacy in chemotherapy-refractory GTN, an ultra-rare cancer affecting young women. Three of 4 patients achieved ongoing objective responses with a reasonable safety profile at 6-11+ months.
    MeSH term(s) Pregnancy ; Humans ; Female ; Nivolumab/therapeutic use ; Ipilimumab/therapeutic use ; Prospective Studies ; Melanoma/drug therapy ; Gestational Trophoblastic Disease/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab
    Language English
    Publishing date 2023-10-26
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-2293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

    Goodman, Aaron / Patel, Sandip P / Kurzrock, Razelle

    Nature reviews. Clinical oncology

    2017  Volume 14, Issue 4, Page(s) 203–220

    Abstract: Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint. Indeed, therapeutic antibodies that block the PD-1-PD-L1 axis ... ...

    Abstract Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint. Indeed, therapeutic antibodies that block the PD-1-PD-L1 axis induce durable clinical responses against a growing list of solid tumours. B-cell lymphomas also leverage this checkpoint to escape immune recognition, although the outcomes of PD-1-PD-L1 blockade, and the correlations between PD-L1 expression and treatment responses, are less-well elucidated in these diseases than in solid cancers. Nevertheless, in patients with Hodgkin lymphoma, amplification of the gene encoding PD-L1 is commonly associated with increased expression of this protein on Reed-Sternberg cells. Correspondingly, PD-1 blockade with nivolumab has been demonstrated to result in response rates as high as 87% in unselected patients with relapsed and/or refractory Hodgkin lymphoma, leading to the FDA approval of nivolumab for this indication in May 2016. The PD-1/PD-L1 axis is probably also important for immune evasion of B-cell lymphomas with a viral aetiology, including those associated with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV). This Review is focused on the role of PD-1-PD-L1 blockade in unleashing host antitumour immune responses against various B-cell lymphomas, and summarizes the clinical studies of this approach performed to date.
    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; CTLA-4 Antigen/immunology ; Clinical Trials as Topic ; Hodgkin Disease/drug therapy ; Hodgkin Disease/immunology ; Humans ; Immunity, Cellular/immunology ; Immunotherapy/methods ; Lymphoma, B-Cell/drug therapy ; Lymphoma, B-Cell/immunology ; Lymphoma, Follicular/drug therapy ; Lymphoma, Follicular/immunology ; Mediastinal Neoplasms/immunology ; Mediastinal Neoplasms/therapy ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Tumor Escape/immunology
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; B7-H1 Antigen ; CTLA-4 Antigen ; CTLA4 protein, human ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2017-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2491410-1
    ISSN 1759-4782 ; 1759-4774
    ISSN (online) 1759-4782
    ISSN 1759-4774
    DOI 10.1038/nrclinonc.2016.168
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top